Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite

Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

By              

Oncology Letters, Vol. 2, Iss. 4, 2011-01 ,pp. : 693-699

Spandidos Publications

Access to resources Recommend Favorite

Soluble Urokinase Plasminogen Activator Receptor in Preoperatively Obtained Plasma from Patients with Gynecological Cancer or Benign Gynecological Diseases

By Riisbro R.   Stephens R.W.   Brunner N.   Christensen I.J.   Nielsen H.J.   Heilmann L.   von Tempelhoff G.-F.  

Gynecologic Oncology, Vol. 82, Iss. 3, 2001-09 ,pp. : 523-531

Elsevier

Access to resources Recommend Favorite

A Comparison of Epidermal Growth Factor Receptor Levels and Other Prognostic Parameters in Non-small Cell Lung Cancer

By Fujino S.   Enokibori T.   Tezuka N.   Asada Y.   Inoue S.   Kato H.   Mori A.  

European Journal of Cancer, Vol. 32, Iss. 12, 1996-11 ,pp. : 2070-2074

Elsevier

Access to resources Recommend Favorite

Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib

By Kanazawa Shigenori   Yamaguchi Kazuyuki   Kinoshita Yoshimi   Komiyama Yutaka   Muramatsu Mikiko   Nomura Shosaku  

Journal of Cancer Research and Clinical Oncology, Vol. 132, Iss. 11, 2006-11 ,pp. : 719-725

Springer Publishing Company

Access to resources Recommend Favorite